Evans A.Dialysis-related carnitine disorder and levocarnitinepharmacology[J]. Am J Kidney Dis,2003, 41(4 Suppl 4): S13-S26.
[2]
Nishizawa Y, Shoji T, Ishimura E, et al. Paradox of risk factors for cardiovascular mortality in uremia: is a higher cholesterol level better for atherosclerosis in uremia[J]. Am J Kidney Dis, 2001, 38 (4 Suppl 1):S4-S7.
[3]
Hurot J M, Cucherat M, Haugh M, et al.Effects of L-carnitine supplementation in maintenance hemodialysis patients:asystem-atic review[J]. J Am SocNephrol,2002, 13(3):708-714.
Terrier N, Jaussent I, Dupuy A M, et al. Creatinine index and transthyretin as additive predictors of mortality in haemodialysispatients[J]. Nephrol Dial Transplant,2008, 23(1): 345-353.
[6]
Barter P, Gotto A M, LaRosa J C, et al. HDL cholesterol, very lowlevels of LDL cholesterol, and cardiovascular events[J]. N Engl J Med,2007, 357(13): 1301-1310.
[7]
Ramharack R, Spahr M A, Sekerke C S, et al. CI-1011 lowers lipoprotein (a) and plasma cholesterolconcentrations in chow-fed cynomolgus monkeys[J].Atherosclerosis,1998,136(1):79-87.
[8]
Elisaf M, Bairaktari E, Katopodis K, et al. Effect of L-carnitine supplementation on lipid parameters inhemodialysis patients[J]. Am J Nephrol, 1998,18(5):416-421.
[9]
Golper T A, Wolfson M, Ahmad S, et al. Multicenter trial of L-carnitine in maintenance hemodialysis patients.Carnitine concentrations and lipid effects[J]. Kidney Int,1990,38(5):904-911.
[10]
Kei Fukami, Sho-ichiYamagishi, Kazuko Sakai,et al.Effects of switching from oral administration to intravenous injection of L-carnitine on lipid meta bolism in hemodialysis patients[J].Clin Kidney J,2014,7(5): 470-474.
[11]
Evans A M, Fornasini G. Pharmacokinetics of L-carnitine[J]. Clin Pharmacokinet, 2003,42(11):941-967.
2016, Vol. 27 
